Findings from a recent study of nearly 4,500 patients hospitalized with COVID-19 over a four-month period provide a stronger case for a very different conclusion: Statins likely did not confer any impact -- positive or negative -- on COVID-related mortality and may be associated with an significantly increased risk -- nearly 1 chance in 5 -- of more serious illness.
Researchers have shown that albino mice of the C57BL/6 line are highly susceptible to developing the inflammatory liver condition non-alcoholic steatohepatitis (NASH) when fed a high cholesterol diet. The albino mice carry a mutation in the tyrosinase gene leading to a deficiency of melanin synthesis. NASH is a serious illness in humans, and the identification of the involvement of tyrosinase in NASH development will guide future research into this condition.
A 'polypill' is a single pill that includes multiple medications to control more than one health risk factor (such as heart disease, high blood pressure, high cholesterol, Type 2 diabetes, kidney disease, stroke). In this large, international trial, the polypill included blood pressure and cholesterol lowering medications for people at risk for heart disease. Results from the randomized, placebo-controlled trial show that the combination of a polypill plus aspirin reduced cardiovascular disease by 31%, and the polypill without aspirin reduced CVD by 21%.
Down syndrome and hypercholesterolemia mouse models suggest that the DSCR-1 gene protects against abnormal cornea vascularization and associated blindness by suppressing oxidized LDL cholesterol production and downstream angiogenic signaling during chronic high cholesterol. While the neurological pathology of Down syndrome patients worsens with age, they are less susceptible to age-related vascular diseases. The responsible genes and mechanisms are not yet clear, but DSCR-1 is a strong candidate for a wide range of vascular diseases.
A medication derived from fish oil, containing the omega-3 fatty acids EPA and DHA, was evaluated in a large, international study of more than 13,000 people who had existing heart disease or who were at high risk of heart disease due to other medical conditions. The medication did not reduce the risk of cardiac events compared to a corn oil-based placebo in the STRENGTH trial.
A 'polypill' is a single pill that includes multiple medications to control more than one health risk factor (such as heart disease, high blood pressure, high cholesterol, Type 2 diabetes, kidney disease, stroke). In this large, international trial, the polypill included blood pressure and cholesterol lowering medications for people at risk for heart disease. Results from the randomized, placebo-controlled trial show that the combination of a polypill plus aspirin reduced cardiovascular disease by 31%, and the polypill without aspirin reduced CVD by 21%.
Down syndrome and hypercholesterolemia mouse models suggest that the DSCR-1 gene protects against abnormal cornea vascularization and associated blindness by suppressing oxidized LDL cholesterol production and downstream angiogenic signaling during chronic high cholesterol. While the neurological pathology of Down syndrome patients worsens with age, they are less susceptible to age-related vascular diseases. The responsible genes and mechanisms are not yet clear, but DSCR-1 is a strong candidate for a wide range of vascular diseases.
Statins are a recommended and common intervention for preventing cardiovascular events by reducing levels of lipoprotein cholesterol in the blood. During the pandemic, it has been debated whether statins influence the risk of death from COVID-19. Researchers have now conducted the largest population study to date in the field. The study indicates that statin treatment slightly lowers COVID-19 mortality.
Researchers have shown that high levels of a specific protein circulating in the blood accurately detect a severe type of peripheral artery disease that narrows the arteries in the legs and can raise the risk of heart attack and stroke.
The new findings offer important insights into how and why the plaques form and may explain why genes associated with cholesterol have been linked to increased risk for Alzheimer's.
Healthy older adults who ate a handful of walnuts (about ½ cup) a day for two years modestly lowered their level of low-density lipoprotein or LDL cholesterol levels. Consuming walnuts daily also reduced the number of LDL particles, a predictor of cardiovascular disease risk. The study explored the effects of a walnut-enriched diet on overall cholesterol in elderly individuals from diverse geographical locations and spanning two years.
Heart attacks and strokes are the main causes of death and loss of productive years globally. These clinical complications are caused by atherosclerosis, which is a chronic disease that leads to the accumulation of LDL cholesterol and immune cells in the inner layer of arteries and thereby resulting in the build-up of atherosclerotic plaques. Researchers have now identified that a cytokine called A Proliferation Inducing Ligand (APRIL) plays a major protective role against the formation of atherosclerotic plaques.
A research team has identified how breast cancer cells use cholesterol to develop tolerance to stress, making them impervious to death as they migrate from the original tumor site.
A potential biomarker predicting severity of heart disease in African American lupus patients was identified in a study conducted by a team of researchers.